A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
| Autor: | Bioque, M, Llerena, A, Cabrera, B, Mezquida, G, Lobo, A, Gonzalez-Pinto, A, Diaz-Caneja, CM, Corripio, I, Aguilar, EJ, Bulbena, A, Castro-Fornieles, J, Vieta, E, Lafuente, A, Mas, S, Parellada, M, Saiz-Ruiz, J, Cuesta, MJ, Bernardo, M |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Psychiatric Status Rating Scales Adolescent polytherapy psychotropic drugs schizophrenia Antipsychotic Pharmacovigilance Young Adult Logistic Models Sex Factors Treatment Outcome Psychotic Disorders Spain first episode psychosis Acute Disease Polypharmacy Humans Female Child Antipsychotic Agents |
| Zdroj: | Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
| ISSN: | 1461-1457 |
| Popis: | Background: The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. Methods: Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. Results: The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P = .043). A total of 5.2% of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|